Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the evolving role of noninvasive neuromodulation in promoting brain plasticity. [WATCH TIME: 3 minutes]

Enhancing Brain Plasticity by Personalized and Closed-Loop Neuromodulation: Roy H. Hamilton, MD, MS, FAAN

Articles

A study involving 20 patients with ALS found that longitudinal muscle MRI detected progressive atrophy and correlated with muscle strength loss, supporting its potential as a biomarker for ALS progression and clinical trials.

Muscle MRI May Serve as Sensitive Biomarker for ALS Disease Progression

This episode explores treatment considerations for patients already living with SMA, emphasizing individualized goals, medical complexity, and the value of subtle clinical improvements.

Setting Realistic Goals for Long-Standing Spinal Muscular Atrophy

Evan L. Smith, PhD, assistant professor of Physical Medicine & Rehabilitation at University of Michigan, discussed how emotional wellbeing, motivation, and evidence-based therapies can significantly influence outcomes in MS.

Psychological Perspective on the Role of Mental Health in MS Rehabilitation and Care

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

, has been with the team since September 2022. Follow her on Twitter 

In this episode, neurologists unpack the urgent and complex treatment decisions in newly diagnosed SMA, highlighting clinical factors, family input, and the importance of shared decision-making.

Starting Treatment in SMA: What Clinicians Need to Consider

The research portfolio director at the Muscular Dystrophy Association highlighted advances in gene-targeted therapies and biomarker development as potential key drivers of progress in ALS.

NeuroVoices: Brian Lin, PhD, on Targeted Therapies and Biomarkers to Drive New Momentum in ALS Research

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAN 2025

AD/PD 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

The Special Reports video series features a variety of clinicians providing updates on the major data and paradigm-affecting updates from societal meetings and conferences focused on patients with neurologic diseases. It also includes the RX Reports bonus series, which focuses on new therapeutics and FDA approvals.

1rem

Movement disorders expert Fernando L Pagan, MD, provides commentary on several presentations of innovative therapies for Parkinson disease from the 2025 American Academy of Neurology Annual Meeting.

AAN 2025: Evolving Therapeutic Approaches for Parkinson Disease

Movement disorders expert Fernando L Pagan, MD, shares insights on emerging therapeutics for Parkinson disease, reflects on the evolution of the neurology field, and offers practical guidance for clinicians.

AAN 2025: A Clinical Perspective on Progress in Parkinson Disease

Aravindhan Veerapandiyan, MD, discusses how del-zota (delpacibart zotadirsen), an exon 44 skipping agent using antibody-conjugated phosphorodiamidate morpholino oligomer (PMO) technology, demonstrated favorable safety, significant dystrophin production (25% of normal), and unprecedented reduction of creatine kinase levels to near-normal in patients with Duchenne muscular dystrophy (DMD) during phase 1/2 clinical trials.

Del-Zota Produced Statistically Significant Increases in Exon-Skipping and Dystrophin Levels in EXPLORE44, a Phase 1/2 Study in Individuals With DMD44

Movement disorder and Parkinson disease specialist Stuart Isaacson, MD, discussed SPN-830 after the subcutaneous apomorphine infusion device's FDA approval.

Special Report: SPN-830 Approved To Treat Parkinson Disease

Multiple sclerosis experts Patricia Coyle, MD, FAAN, and Adnan Subei, DO, FAAN, cover the long-term impacts of S1P-modulating treatments for MS, the differences in each treatment, and how the class has evolved since the first therapeutic over 10 years ago. 

Multimodal Actions of S1P Receptor Modulators in Multiple Sclerosis

Movement disorder experts Robert Hauser, MD, MBA, and Hubert Fernandez, MD, discuss the recently approved IPX203 (Crexont; Amneal Pharmaceuticals) for the treatment of patients with Parkinson disease. 

Special Report: IPX203 as New Treatment for Parkinson Disease

Multiple Sclerosis expert Donald Negroski, MD, provides clinical insight on a number of abstracts from the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting focused on treatment changes and care for aging patients with MS.

CMSC 2024: Navigating Treatment Switches and Aging in MS

Parkinson disease expert Daniel Kremens, MD, JD, offers commentary on various presentations of novel therapies from the 2024 American Academy of Neurology Annual Meeting.

AAN 2024: Novel Approaches to Parkinson Disease Care

Highlights from the 2023 World Stroke Congress are provided through medical expert perspectives.

Key Takeaways From 2023 World Stroke Congress

Multiple sclerosis experts discuss long-term safety and efficacy data on S1P receptors modulators and other updates from EAN 2023.

Global Multiple Sclerosis News Network - Insights on EAN's Annual Data Releases in MS

An expert neurologist discusses the use of neurofilament light chain (NfL) as a biomarker in multiple sclerosis (MS), highlighting clinical trials and updates from a recent conference.

AAN 2023: Neurofilament Light Chain and Disease Progression in Multiple Sclerosis

Stuart H. Isaacson, MD, FAAN, an expert in the care of patients with Parkinson disease, discusses data on novel treatments for Parkinson disease and how these therapies can affect the care paradigm.

AAN 2023: Optimizing Control of Parkinson's Disease With Newer Delivery Options

Stuart H. Isaacson, MD, FAAN, an expert in the care of patients with Parkinson disease, shares in-depth perspectives on personalizing management plans and data from the 2023 AAN Annual Meeting.

AAN 2023: Improving Outcomes in Parkinson's Disease Through Personalization of Treatment

Experts in the management of multiple sclerosis discuss the latest understanding of how disease progression and treatment affect cognition.

AAN 2023: Cognition and Disease Modifying Therapies in Multiple Sclerosis

Multiple sclerosis experts discuss data from four presentations on ozanimod, a disease modifying therapy that was presented at EAN 2022.

EAN News Network

Key opinion leaders and presenters offer their insight on the latest advances in the management of patients with multiple sclerosis at the 2022 Consortium of Multiple Sclerosis Centers annual meeting.

Consortium of MS Centers 2022: News Network

Key opinion leaders and presenters at the 2022 American Academy of Neurology annual meeting share their perspectives on the latest advances in the management of patients with multiple sclerosis.

American Academy of Neurology 2022: Multiple Sclerosis Highlights

Key opinion leaders and presenters at the ACTRIMS Forum 2022 share their perspectives on the latest data and updates in the management of patients with multiple sclerosis (MS).

ACTRIMS Forum 2022: News Network

Leading physicians in the treatment of multiple sclerosis (MS) offer insights into presentations and data readouts from the 2021 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.

CMSC 2021: Updates in MS

Experts in the treatment of multiple sclerosis (MS) offer insights into data presented at the 2021 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

ECTRIMS Congress 2021: Updates in MS

Trevor J. Resnick, MD, and Amit Verma, MD, review data presented at the American Epilepsy Society (AES) Annual Meeting 2020.

Treating Epilepsy: Key Takeaways From AES 2020

Experts in multiple sclerosis review top data presented at the 8th joint ACTRIMS-ECTRIMS meeting. 